The United States Food and Drug Administration (USFDA) has approved Cosentyx (Secukinumab) for treatment of active psoriatic arthritis (PsA) and active ankylosing spondylitis (AS) in adults.
Cosentyx is the first and only approved interleukin-17A (IL-17A) antagonist for AS and moderate to severe PsA.
Placebo-controlled phase III clinical trials were conducted which included over 1500 adults with either PsA or AS. When compared to placebo group subjects, statistically significant clinical improvement with at least 20% improvement in the Assessment of Spondyloarthritis International Society Criteria (ASAS20) at week 16 was observed in Cosentyx group.
At week 24, 20% reduction in the American College of Rheumatology (ACR20) response criteria was reported in AS and PsA patients.